Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence

BACKGROUND: In clinical trials enrolling patients with type 2 diabetes (T2D) at high cardiovascular risk, many glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improved albuminuria status and possibly mitigated kidney function loss. However, limited data are available regarding the effects of G...

Descripción completa

Detalles Bibliográficos
Autores principales: Schechter, Meir, Melzer Cohen, Cheli, Fishkin, Alisa, Rozenberg, Aliza, Yanuv, Ilan, Sehtman-Shachar, Dvora R., Chodick, Gabriel, Clark, Alice, Abrahamsen, Trine J., Lawson, Jack, Karasik, Avraham, Mosenzon, Ofri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225085/
https://www.ncbi.nlm.nih.gov/pubmed/37244998
http://dx.doi.org/10.1186/s12933-023-01829-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225085/
https://www.ncbi.nlm.nih.gov/pubmed/37244998
http://dx.doi.org/10.1186/s12933-023-01829-0

Ejemplares similares